Palbociclib - CISMeF

Preferred Label : Palbociclib;

NCIt synonyms : 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-;

NCIt definition : An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.;

UNII : G9ZF61LE7G;

InChIKey : AHJRHEGDXFFMBM-UHFFFAOYSA-N;

CAS number : 571190-30-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 571190-30-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Ibrance;

Molecule name : PD-0332991; PD 991; PD 0332991; PD 332991;

Chemical formula : C24H29N7O2;

Codes from synonyms : 381;

Details

Origin ID

C49176;

UMLS CUI

C3853822;

Automatic exact mappings (from CISMeF team)
- Palbociclib [ICD-11 Extension code]
- palbociclib [ATC Code]
Currated CISMeF NLP mapping
- Palbociclib (substance) [SNOMED CT concept]
- palbociclib [MeSH concept]
- palbociclib [MeSH Supplementary Concept]
See also inter- (CISMeF)
- PD 0332991 [MeSH concept]
- Product containing palbociclib (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Palbociclib (substance) [SNOMED CT concept]
- Product containing palbociclib (medicinal product) [SNOMED CT concept]
- palbociclib [MeSH Supplementary Concept]
- palbociclib [ATC Code]
chemical_or_drug_affects_gene_product
- Cyclin-Dependent Kinase [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Enzyme Inhibition [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Gene Regulation Process [NCIt concept]
- Negative Regulation of G1 Phase [NCIt concept]
- Negative Regulation of G2 to M Transition [NCIt concept]
- Positive Regulation of Apoptosis [NCIt concept]
- Protein Phosphorylation Inhibition [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_salt_form
- Palbociclib Isethionate [NCIt concept]
has_target
- Cyclin-Dependent Kinase 4 [NCIt concept]
- Cyclin-Dependent Kinase 6 [NCIt concept]
is_component_of_chemotherapy_regimen
- Anastrozole/Palbociclib Regimen [NCIt concept]
- Exemestane/Palbociclib Regimen [NCIt concept]
- Fulvestrant/Palbociclib Regimen [NCIt concept]
- Letrozole/Leuprolide/Palbociclib Regimen [NCIt concept]
- Letrozole/Palbociclib Regimen [NCIt concept]
- Palbociclib Regimen [NCIt concept]
- Palbociclib/Tamoxifen Regimen [NCIt concept]
is_free_acid_or_base_form_of
- Palbociclib Isethionate [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients